New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Valeant Pharmaceuticals International's proposed $475M acquisition of Precision Dermatology. would likely be anticompetitive. Under the order, Valeant has agreed to sell Precision’s assets related to two acne treatments – Tretin-X, its branded single-agent topical tretinoin, and generic Retin-A – within 10 days of consummating the transaction. According to the FTC’s complaint, first announced in July, Valeant’s acquisition of Precision as originally proposed would likely reduce competition in the market for branded and generic single-agent topical tretinoins, and in a separate market for generic Retin-A. Reference Link
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
10:19 EDTVRXPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use